DXCM vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DXCM and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DXCM is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | DXCM | TAK |
|---|---|---|
| Company Name | DexCom, Inc. | Takeda Pharmaceutical Company Limited |
| Country | United States | Japan |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 31.36 billion USD | 46.65 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 14, 2005 | January 5, 2010 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DXCM and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DXCM | TAK |
|---|---|---|
| 5-Day Price Return | 4.66% | 2.78% |
| 13-Week Price Return | -5.98% | 5.93% |
| 26-Week Price Return | -9.47% | 5.75% |
| 52-Week Price Return | 12.19% | 5.51% |
| Month-to-Date Return | -1.00% | 3.74% |
| Year-to-Date Return | 2.82% | 4.21% |
| 10-Day Avg. Volume | 5.06M | 5.48M |
| 3-Month Avg. Volume | 3.92M | 4.67M |
| 3-Month Volatility | 36.35% | 15.38% |
| Beta | 1.49 | 0.42 |
Profitability
Return on Equity (TTM)
DXCM
25.62%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
In the upper quartile for the Health Care Equipment & Supplies industry, DXCM’s Return on Equity of 25.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
TAK
1.48%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TAK’s Return on Equity of 1.48% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
DXCM
13.29%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
A Net Profit Margin of 13.29% places DXCM in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
TAK
2.36%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 2.36% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
DXCM
15.98%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
DXCM’s Operating Profit Margin of 15.98% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
TAK
7.48%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TAK’s Operating Profit Margin of 7.48% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | DXCM | TAK |
|---|---|---|
| Return on Equity (TTM) | 25.62% | 1.48% |
| Return on Assets (TTM) | 8.49% | 0.72% |
| Net Profit Margin (TTM) | 13.29% | 2.36% |
| Operating Profit Margin (TTM) | 15.98% | 7.48% |
| Gross Profit Margin (TTM) | 60.01% | 65.51% |
Financial Strength
Current Ratio (MRQ)
DXCM
1.52
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
DXCM’s Current Ratio of 1.52 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
TAK
1.01
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TAK’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DXCM
0.97
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
DXCM’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.97. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
TAK
0.65
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DXCM
978.00
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
With an Interest Coverage Ratio of 978.00, DXCM demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
TAK
2.05
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 2.05 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | DXCM | TAK |
|---|---|---|
| Current Ratio (MRQ) | 1.52 | 1.01 |
| Quick Ratio (MRQ) | 1.32 | 0.52 |
| Debt-to-Equity Ratio (MRQ) | 0.97 | 0.65 |
| Interest Coverage Ratio (TTM) | 978.00 | 2.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
DXCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TAK
4.39%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.39%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
DXCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TAK
138.69%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 138.69% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | DXCM | TAK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.39% |
| Dividend Payout Ratio (TTM) | 0.00% | 138.69% |
Valuation
Price-to-Earnings Ratio (TTM)
DXCM
55.47
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
A P/E Ratio of 55.47 places DXCM in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
TAK
63.81
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 63.81, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
DXCM
7.37
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
DXCM’s P/S Ratio of 7.37 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
TAK
1.50
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.50 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
DXCM
13.30
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
At 13.30, DXCM’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
TAK
1.01
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TAK’s P/B Ratio of 1.01 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | DXCM | TAK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 55.47 | 63.81 |
| Price-to-Sales Ratio (TTM) | 7.37 | 1.50 |
| Price-to-Book Ratio (MRQ) | 13.30 | 1.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 55.54 | 9.71 |